Abstract
Acute myeloid leukemia (AML) with pseudo-Chèdiak-Higashi (PCH) anomaly is a rare morphologic entity. We characterized 5 cases by multiparameter flow cytometry and found that in all cases, the blasts aberrantly expressed CD2, a pan-T cell-associated marker, in addition to their myeloid-associated markers. In contrast, CD2 was expressed in only 25 (17.9%) of 140 cases of newly diagnosed AML without PCH anomaly. CD2 expression correlated strongly with AML with PCH anomaly (P < .01), suggesting a link between a specific immunophenotypic marker, CD2, and AML with PCH anomaly.
MeSH terms
-
Acute Disease
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor / metabolism
-
CD2 Antigens / metabolism*
-
Chediak-Higashi Syndrome / complications
-
Chediak-Higashi Syndrome / drug therapy
-
Chediak-Higashi Syndrome / metabolism
-
Chediak-Higashi Syndrome / pathology*
-
Female
-
Flow Cytometry
-
Humans
-
Immunophenotyping*
-
Karyotyping
-
Leukemia, Myeloid / complications
-
Leukemia, Myeloid / drug therapy
-
Leukemia, Myeloid / metabolism
-
Leukemia, Myeloid / pathology*
-
Male
-
Middle Aged
-
Treatment Outcome
Substances
-
Biomarkers, Tumor
-
CD2 Antigens